Get the Stockscreener App
5.905
3.06%
-0.185
Verastem Inc stock is traded at $5.905, with a volume of 269.14K.
It is down -3.06% in the last 24 hours and down -9.73% over the past month.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$6.09
Open:
$6.09
24h Volume:
269.14K
Relative Volume:
0.20
Market Cap:
$271.04M
Revenue:
$3.64M
Net Income/Loss:
$-87.37M
P/E Ratio:
-1.4367
EPS:
-4.11
Net Cash Flow:
$-86.46M
1W Performance:
-2.90%
1M Performance:
-9.73%
6M Performance:
+165.93%
1Y Performance:
-56.11%
1-Day Range:
$5.76
$6.11
1-Week Range:
$5.60
$6.1599
52-Week Range:
$2.10
$14.09
Verastem Inc Stock (VSTM) Company Profile
Name
Verastem Inc
Sector
Industry
Phone
(781) 292-4200
Address
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
5.91 | 271.04M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.76 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.62 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.19 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.15 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.44 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-31-24 | Reiterated | BTIG Research | Buy |
| Sep-30-24 | Initiated | Guggenheim | Buy |
| Nov-21-23 | Resumed | BTIG Research | Buy |
| Sep-27-23 | Initiated | B. Riley Securities | Buy |
| Jun-15-23 | Upgrade | Mizuho | Neutral → Buy |
| Sep-07-22 | Resumed | Alliance Global Partners | Buy |
| Apr-29-22 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-14-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-09-22 | Initiated | Truist | Buy |
| Jul-01-21 | Initiated | Alliance Global Partners | Buy |
| May-24-21 | Upgrade | BTIG Research | Neutral → Buy |
| Jun-20-19 | Downgrade | BTIG Research | Buy → Neutral |
| May-10-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-13-18 | Initiated | BTIG Research | Buy |
| May-02-18 | Initiated | Seaport Global Securities | Buy |
| Mar-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-07-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-17 | Initiated | Oppenheimer | Outperform |
| Mar-24-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-29-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Sep-29-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-29-15 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-15 | Downgrade | Raymond James | Strong Buy → Outperform |
| Sep-28-15 | Downgrade | Mizuho | Buy → Neutral |
| Sep-28-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| May-12-15 | Reiterated | UBS | Buy |
| Apr-08-15 | Initiated | H.C. Wainwright | Buy |
| Jan-23-15 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Oppenheimer | Perform |
| Feb-11-14 | Initiated | Mizuho | Buy |
View All
Verastem Inc Stock (VSTM) Latest News
The time has not yet come to remove your chips from the table: Verastem Inc (VSTM) - SETE News
Recent Insider Activity Could Benefit Verastem Inc (VSTM) - Knox Daily
Verastem CEO Dan Paterson sells shares worth $4,890 - MSN
Verastem, Inc. (NASDAQ:VSTM) Shares Acquired by JPMorgan Chase & Co. - Defense World
Verastem (NASDAQ:VSTM) Given New $9.00 Price Target at B. Riley - MarketBeat
Verastem, Inc. (NASDAQ:VSTM) Sees Large Increase in Short Interest - MarketBeat
Financial Metrics Check: Verastem Inc (VSTM)’s Ratios for Trailing Twelve Months - The Dwinnex
B. Riley Forecasts Strong Price Appreciation for Verastem (NASDAQ:VSTM) Stock - Defense World
Brokerages Set Verastem, Inc. (NASDAQ:VSTM) PT at $13.38 - MarketBeat
Vanguard Group Inc. Increases Stake in Verastem Inc. - GuruFocus.com
Verastem price target raised to $9 from $7 at B. Riley - MSN
B. Riley Adjusts Verastem's Price Target to $9 From $7, Maintains Buy Rating -January 31, 2025 at 09:19 am EST - Marketscreener.com
Verastem Licenses Investigational Cancer Drug VS-7375 from GenFleet, Shares Rise 4.1% – Market - HPBL
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference - Yahoo Finance
Verastem Exercises Option for VS-7375 Targeting RAS Pathway Driven CancersVerastem, Inc. (NASDAQ:VSTM) has announced the exercise of its option with regards to VS-7375, which is an oral and selective KRAS G12D (ON/OFF) inhibitor. This move signif - Defense World
Guggenheim Reiterates Buy Rating for Verastem (NASDAQ:VSTM) - Defense World
Verastem's (VSTM) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Mizuho maintains Verastem stock outperform with $9 target By Investing.com - Investing.com Australia
Mizuho maintains Verastem stock outperform with $9 target - MSN
Cantor Fitzgerald Estimates Verastem FY2025 Earnings - Defense World
Verastem Stock Soars 46% After FDA Grants Priority Review for Cancer Treatment – Market - HPBL
Cantor Fitzgerald Forecasts Verastem FY2025 Earnings - MarketBeat
Verstem avutometinib and defactinib combo gains FDA priority review - Seeking Alpha
Verastem Expands Oncology Pipeline with VS-7375 Acquisition - TipRanks
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire
Barclays PLC Acquires 47,094 Shares of Verastem, Inc. (NASDAQ:VSTM) - MarketBeat
KRAS Inhibitors Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Novartis, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly, Revolution Medicines - Barchart
Verastem appoints new COO with extensive biotech experience By Investing.com - Investing.com South Africa
Verastem appoints new COO with extensive biotech experience - Investing.com India
Verastem Appoints Matthew E. Ros as COO - TipRanks
Verastem Secures $150 Million Note Purchase Agreement with Oberland Capital - Defense World
Verastem stock retains Buy rating as KRASG12D program and LGSOC launch gain traction - Investing.com Canada
Verastem, Inc. (NASDAQ:VSTM) Shares Sold by Jane Street Group LLC - Defense World
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer - BioSpace
Verastem Oncology Names Pharma Veteran Matthew Ros as COO Ahead of Key Cancer Drug Launch - StockTitan
Verastem Oncology Appoints Matthew E. Ros as Chief Operating Officer - Marketscreener.com
Dan Paterson Sells 8,568 Shares of Verastem, Inc. (NASDAQ:VSTM) Stock - MarketBeat
Verastem CEO sells shares worth $44,896 By Investing.com - Investing.com Australia
Verastem CEO sells shares worth $44,896 - Investing.com India
Verastem Inc Stock (VSTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Verastem Inc Stock (VSTM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Paterson Dan | President and CEO |
Jan 13 '25 |
Sale |
5.24 |
8,568 |
44,896 |
347,581 |
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):